Brought to you by 
Shire grants Prasco exclusive rights to sell generic Fosrenol in the US
02 Dec 2013
Executive Summary
Generics company Prasco Laboratories will exclusively market, distribute, and supply an authorized generic of Shire PLC’s Fosrenol (lanthanum) chewable tablets in the US.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shire grants Prasco exclusive rights to sell generic Fosrenol in the US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice